Published in J Infect Dis on December 23, 2013
GS-7977 With Ribavirin for Hepatitis C (SPARE) | NCT01441180
Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis (2014) 2.06
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res (2014) 1.32
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 1.12
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun (2014) 1.01
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol (2015) 0.99
Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. Open Forum Infect Dis (2014) 0.97
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One (2014) 0.89
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes Immun (2015) 0.86
Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells. J Interferon Cytokine Res (2015) 0.86
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis (2015) 0.84
IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. Int J Hepatol (2014) 0.83
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother (2015) 0.82
Perceptions of genetic testing and genomic medicine among drug users. Int J Drug Policy (2014) 0.80
IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System. PLoS One (2015) 0.78
IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. PLoS One (2015) 0.78
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infect Dis (2015) 0.77
Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep (2015) 0.77
Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med (2016) 0.76
Interferon lambda 4 (IFNL4) gene polymorphism is associated with spontaneous clearance of HCV in HIV-1 positive patients. Genet Mol Biol (2016) 0.76
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med (2017) 0.75
Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C. PLoS One (2016) 0.75
IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research. Gastroenterol Res Pract (2015) 0.75
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res (2017) 0.75
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev (2016) 0.75
IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol (2017) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2013) 1.50
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol (2011) 1.45
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43
Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J (2013) 1.40
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat (2012) 1.17
Maximum likelihood estimation in dynamical models of HIV. Biometrics (2007) 1.11
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 43.16
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol (2009) 9.43
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep (2002) 4.64
Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control (2011) 4.59
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis (2011) 4.09
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med (2008) 3.67
Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology (2012) 3.37
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell (2013) 3.30
Treatment of hepatitis C virus infection: is it time for the internist to take the reins? Ann Intern Med (2014) 3.28
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med (2014) 3.17
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Top-down control of human visual cortex by frontal and parietal cortex in anticipatory visual spatial attention. J Neurosci (2008) 3.07
A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res (2009) 2.86
Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep (2002) 2.86
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 2.70
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-related Infections. Clin Infect Dis (2011) 2.49
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol (2006) 2.48
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood (2008) 2.27
Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol (2002) 2.24
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Sepsis: time to reconsider the concept. Crit Care Med (2008) 2.17
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 2.12
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep (2004) 2.05
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends (2010) 2.01
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res (2013) 1.99
Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J (2005) 1.97
Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS (2010) 1.90
Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J Cell Biol (2004) 1.89
The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS (2006) 1.88
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol (2009) 1.86
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron (2008) 1.80
Fighting HIV/AIDS in Washington, D.C. Health Aff (Millwood) (2009) 1.77
High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med (2002) 1.74
Draft genome of the kiwifruit Actinidia chinensis. Nat Commun (2013) 1.72
Wnt signaling activation in adipose progenitors promotes insulin-independent muscle glucose uptake. Cell Metab (2012) 1.72
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int (2008) 1.68
Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol (2011) 1.66
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
New kinetic models for the hepatitis C virus. Hepatology (2005) 1.63
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med (2006) 1.62
Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis (2003) 1.62
The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology (2007) 1.61
NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy. Kidney Int (2013) 1.61
Diminishing catalyst concentration in atom transfer radical polymerization with reducing agents. Proc Natl Acad Sci U S A (2006) 1.61
A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet (2011) 1.60
Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol (2002) 1.59
Intractable and rare diseases research in Asia. Biosci Trends (2012) 1.59
Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol (2002) 1.56
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 1.53
Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J (2010) 1.53
Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis (2007) 1.52
Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. J Infect Dis (2007) 1.50
Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA (2009) 1.50
Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis (2011) 1.49
Contrast-Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a meta-analysis. Liver Int (2013) 1.49
MR imaging of acute pancreatitis: correlation of abdominal wall edema with severity scores. Eur J Radiol (2012) 1.47
Long-term results and cusp dynamics after aortic valve resuspension for aortic root aneurysms. Ann Thorac Surg (2011) 1.47
A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A (2006) 1.46